Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Open accessPublished version of a preprint
Abstract
Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer’s disease (AD), reflecting abnormal tau metabolism in the brain. Here we investigate the performance of CSF p-tau217 as a biomarker of AD in comparison to p-tau181. In the Swedish BioFINDER cohort ( n = 194), p-tau217 shows stronger correlations with the tau positron emission tomography (PET) tracer [ 18 F]flortaucipir, and more accurately identifies individuals with abnormally increased [ 18 F]flortaucipir retention. Furthermore, longitudinal increases in p-tau217 are higher compared to p-tau181 and better correlate with [ 18 F]flortaucipir uptake. P-tau217 correlates better than p-tau181 with CSF and PET measures of neocortical amyloid-β burden and more accurately distinguishes AD dementia from non-AD neurodegenerative disorders. Higher correlations between p-tau217 and [ 18 F]flortaucipir are corroborated in an independent EXPEDITION3 trial cohort ( n = 32). The main results are validated using a different p-tau217 immunoassay. These findings suggest that p-tau217 might be more useful than p-tau181 in the diagnostic work up of AD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CSF p-tau217 correlates better with Aβ and tau PET imaging than CSF p-tau181.
“In addition, CSF p-tau217 correlates better with Aβ and tau PET imaging than CSF p-tau181.24,30”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [24]
CSF p-tau217 might better discriminate AD from other neurodegenerative diseases than CSF p-tau181.
“Recent reports have suggested that CSF p-tau217 might better discriminate AD from other neurodegenerative diseases24,27, 28, 29, 30 than CSF p-tau181.”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · see citing works
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · see citing works
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027 · see citing works
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822 · see citing works
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · see citing works
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734 · see citing works
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605 · see citing works
Self-citationBuerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., et al. (2006) · Brain · doi:10.1093/brain/awl269 · Cited by 586 · see citing works
Tau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586 · see citing works
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564 · see citing works
In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum
Cho, H., Choi, J. Y., Hwang, M. S., Kim, Y. J., Lee, H. M., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2016) · Annals of Neurology · doi:10.1002/ana.24711 · Cited by 499 · see citing works
Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1358 · Cited by 368 · see citing works
Self-citationJanelidze, S., Pannee, J., Mikulskis, A., Chiao, P., Zetterberg, H., Blennow, K., & Hansson, O. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2814 · Cited by 147 · see citing works
Flortaucipir F 18 quantitation using parametric estimation of reference signal intensity.
Southekal, S., Devous, M. D., Kennedy, I., Navitsky, M., Lu, M., Joshi, A. D., Pontecorvo, M. J., & Mintun, M. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200006 · Cited by 92 · see citing works
Test-retest reproducibility for the tau PET imaging agent flortaucipir F 18.
Devous, M. D., Joshi, A. D., Navitsky, M., Southekal, S., Pontecorvo, M. J., Shen, H., Lu, M., Shankle, W. R., Seibyl, J. P., Marek, K., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200691 · Cited by 79 · see citing works
Palmqvist, S., Insel, P. S., Zetterberg, H., Blennow, K., Brix, B., Stomrud, E., Initiative, T. A. D. N., study, T. S. B., Mattsson, N., & Hansson, O. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.014 · Cited by 65 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 42
- [1]Scheltens P Alzheimer’s disease Lancet 2016 388 505 517 26921134
- [2]Alonso AD Beharry C Corbo CP Cohen LS Molecular mechanism of prion-like tau-induced neurodegeneration Alzheimers Dement 2016 12 1090 1097 27126544
- [3]Hanger DP Anderton BH Noble W Tau phosphorylation: the therapeutic challenge for neurodegenerative disease Trends Mol. Med. 2009 15 112 119 19246243
- [4]Hernandez F Avila J Tauopathies Cell Mol. Life Sci. 2007 64 2219 2233 17604998 PMC11136052
- [5]Olsson B CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis Lancet Neurol. 2016 15 673 684 27068280
- [8]Dubois B Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria Lancet Neurol. 2014 13 614 629 24849862
- [9]Molinuevo JL Current state of Alzheimer’s fluid biomarkers Acta Neuropathol. 2018 136 821 853 30488277 PMC6280827
- [11]Buchhave P Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia Arch. Gen. Psychiatry 2012 69 98 106 22213792
- [13]Lleo A A 2-Step cerebrospinal algorithm for the selection of frontotemporal lobar degeneration subtypes JAMA Neurol. 2018 75 738 745 29554190 PMC5885205
- [14]Schoonenboom NS Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort Neurology 2012 78 47 54 22170879
- [16]Tapiola T Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Arch. Neurol. 2009 66 382 389 19273758
- [18]Chhatwal JP Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly Neurology 2016 87 920 926 27473132 PMC5035159
- [19]Mattsson N (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease EMBO Mol. Med. 2017 9 1212 1223 28743782 PMC5582410
- [20]Mattsson N Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease Neurology 2018 90 e388 e395 29321235 PMC5791788
- [21]Gordon BA The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging Brain 2016 139 2249 2260 27286736 PMC4958902
- [22]Hampel H Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study Arch. Gen. Psychiatry 2004 61 95 102 14706948
- [25]Ossenkoppele R Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease Neurology 2019 92 e601 e612 30626656 PMC6382060
- [26]Ossenkoppele R Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders JAMA 2018 320 1151 1162 30326496 PMC6233630
- [29]Lowe VJ An autoradiographic evaluation of AV-1451 Tau PET in dementia Acta Neuropathol. Commun. 2016 4 58 27296779 PMC4906968
- [30]Marquie, M. et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 78, 787–800 (2015). PMC4900162 26344059
- [31]Sander K Characterization of tau positron emission tomography tracer [(18)F]AV-1451 binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and other dementias Alzheimers Dement 2016 12 1116 1124 26892233
- [32]Smith Ruben Wibom Moa Pawlik Daria Englund Elisabet Hansson Oskar Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology JAMA Neurology 2019 76 3 310 30508025 PMC6439731
- [33]Zheng-Fischhofer Q Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation Eur. J. Biochem. 1998 252 542 552 9546672
- [34]Hanger DP Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis J. Biol. Chem. 2007 282 23645 23654 17562708
- [35]Yoshida H Goedert M Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin generates the AT100 epitope J. Neurochem. 2006 99 154 164 16987243
- [36]Spillantini MG Crowther RA Goedert M Comparison of the neurofibrillary pathology in Alzheimer’s disease and familial presenile dementia with tangles Acta Neuropathol. 1996 92 42 48 8811124
- [39]Blennow K Mattsson N Scholl M Hansson O Zetterberg H Amyloid biomarkers in Alzheimer’s disease Trends Pharm. Sci. 2015 36 297 309 25840462
- [40]Barthélemy, N. R. et al. Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid-β pathology. bioRxiv, 10.1101/226977 (2017). · DOI
- [41]Hansson O The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer’s disease diagnosis: a review Alzheimers Dement 2018 14 1313 1333 29940161
- [42]Shaw LM Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease Alzheimers Dement 2018 14 1505 1521 30316776 PMC10013957
- [43]Petersen RC Mild cognitive impairment as a diagnostic entity J. Intern. Med. 2004 256 183 194 15324362
- [47]Litvan I Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop Neurology 1996 47 1 9 8710059
- [48]McKeith IG Perry EK Perry RH Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies Neurology 1999 53 902 905 10496243
- [49]Lang, A. E., Riley D. E., Bergeron C. Cortical-basal ganglionic degeneration. in Neurodegenerative Diseases (ed. Calne D. B.). (W.B. Saunders, 1994).
- [50]Gorno-Tempini ML Classification of primary progressive aphasia and its variants Neurology 2011 76 1006 1014 21325651 PMC3059138
- [51]Rascovsky K Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia Brain 2011 134 2456 2477 21810890 PMC3170532
- [54]Hahn A Modeling strategies for quantification of in vivo (18)F-AV-1451 binding in patients with Tau pathology J. Nucl. Med. 2017 58 623 631 27765859
- [55]Maass A Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer’s disease Neuroimage 2017 157 448 463 28587897 PMC5814575
- [57]Van Essen DC A population-average, landmark- and surface-based (PALS) atlas of human cerebral cortex Neuroimage 2005 28 635 662 16172003
- [58]Palmqvist S Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity Nat. Commun. 2017 8 1214 29089479 PMC5663717
- [64]Robin X pROC: an open-source package for R and S+ to analyze and compare ROC curves BMC Bioinforma. 2011 12 77 PMC3068975 21414208
- [66]Triana-Baltzer, G., et al. Development and validation of a high sensitivity assay for measuring p217+Tau in CSF. J. Alzheimers Dis.62, 737–744 (2018) PMC8158165 34095436
Cited by
Sorted by citations
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606 · see citing works
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · see citing works
Self-citationBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159 · see citing works
Self-citationPlasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719 · see citing works
Thijssen, E. H., La Joie, R., Strom, A., Fonseca, C., Iaccarino, L., Wolf, A., Spina, S., Allen, I. E., Cobigo, Y., Heuer, H., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00214-3 · Cited by 607 · see citing works
Self-citationTau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00168-5 · Cited by 557 · see citing works
Self-citationPalmqvist, S., Tideman, P., Cullen, N., Zetterberg, H., Blennow, K., Initiative, T. A. D. N., Dage, J. L., Stomrud, E., Janelidze, S., Mattsson-Carlgren, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01348-z · Cited by 524 · see citing works
Self-citationHead-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., Vanmechelen, E., He, Y., Dolado, A. O., Triana-Baltzer, G., et al. (2023) · Brain · doi:10.1093/brain/awac333 · Cited by 522 · see citing works
Self-citationBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522 · see citing works
Self-citationBlood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200861 · Cited by 437 · see citing works
Suárez‐Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà‐Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012921 · Cited by 401 · see citing works
Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease
Arnsten, A. F. T., Datta, D., Del Tredici, K., & Braak, H. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12192 · Cited by 361 · see citing works
Tauopathies: new perspectives and challenges
Zhang, Y., Wu, K.-M., Yang, L., Dong, Q., & Yu, J.-T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00533-z · Cited by 323 · see citing works
Hampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.017 · Cited by 283 · see citing works
Self-citationCSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02443-z · Cited by 249 · see citing works
Self-citationMielke, M. M., Frank, R. D., Dage, J. L., Jeromin, A., Ashton, N. J., Blennow, K., Karikari, T. K., Vanmechelen, E., Zetterberg, H., Algeciras-Schimnich, A., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.2293 · Cited by 244 · see citing works
Self-citationAdvances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241 · see citing works
Pichet Binette, A., Janelidze, S., Cullen, N., Dage, J. L., Bateman, R. J., Zetterberg, H., Blennow, K., Stomrud, E., Mattsson‐Carlgren, N., & Hansson, O. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12787 · Cited by 226 · see citing works
Self-citationMoving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Zetterberg, H., & Blennow, K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00430-x · Cited by 219 · see citing works
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Salvadó, G., Ossenkoppele, R., Ashton, N. J., Beach, T. G., Serrano, G. E., Reiman, E. M., Zetterberg, H., Mattsson‐Carlgren, N., Janelidze, S., Blennow, K., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202217123 · Cited by 205 · see citing works
Self-citationMouse Models of Alzheimer’s Disease
Yokoyama, M., Kobayashi, H., Tatsumi, L., & Tomita, T. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.912995 · Cited by 213 · see citing works
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
Ashton, N. J., Benedet, A. L., Pascoal, T. A., Karikari, T. K., Lantero-Rodriguez, J., Brum, W. S., Mathotaarachchi, S., Therriault, J., Savard, M., Chamoun, M., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.103836 · Cited by 184 · see citing works
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
Leuzy, A., Smith, R., Cullen, N. C., Strandberg, O., Vogel, J. W., Binette, A. P., Borroni, E., Janelidze, S., Ohlsson, T., Jögi, J., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4654 · Cited by 149 · see citing works
Self-citationBarthélemy, N. R., Saef, B., Li, Y., Gordon, B. A., He, Y., Horie, K., Stomrud, E., Salvadó, G., Janelidze, S., Sato, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00380-7 · Cited by 153 · see citing works
Self-citationKarikari, T. K., Emeršič, A., Vrillon, A., Lantero‐Rodriguez, J., Ashton, N. J., Kramberger, M. G., Dumurgier, J., Hourregue, C., Čučnik, S., Brinkmalm, G., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12236 · Cited by 143 · see citing works
The informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89 · see citing works
Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
Hall, S., Janelidze, S., Londos, E., Leuzy, A., Stomrud, E., Dage, J. L., & Hansson, O. (2021) · Movement Disorders · doi:10.1002/mds.28370 · Cited by 80 · see citing works
Self-citationChhatwal, J. P., Schultz, A. P., Dang, Y., Ostaszewski, B., Liu, L., Yang, H.-S., Johnson, K. A., Sperling, R. A., & Selkoe, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-19543-w · Cited by 60 · see citing works
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers
Janelidze, S., Christian, B. T., Price, J., Laymon, C., Schupf, N., Klunk, W. E., Lott, I., Silverman, W., Rosas, H. D., Zaman, S., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1740 · Cited by 60 · see citing works
Self-citationComparison of CSF phosphorylated tau 181 and 217 for cognitive decline
Mielke, M. M., Aakre, J. A., Algeciras‐Schimnich, A., Proctor, N. K., Machulda, M. M., Eichenlaub, U., Knopman, D. S., Vemuri, P., Graff‐Radford, J., Jack, C. R., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12415 · Cited by 55 · see citing works
Self-citationQuantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer’s disease
Morshed, N., Lee, M. J., Rodriguez, F. H., Lauffenburger, D. A., Mastroeni, D., & White, F. M. (2021) · Nature Aging · doi:10.1038/s43587-021-00071-1 · Cited by 58 · see citing works
Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease
Rani, S., Dhar, S. B., Khajuria, A., Gupta, D., Jaiswal, P. K., Singla, N., Kaur, M., Singh, G., & Barnwal, R. P. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01330-y · Cited by 48 · see citing works
Diagnostic biomarkers in Alzheimer’s disease
Andersen, E., Casteigne, B., Chapman, W. D., Creed, A., Foster, F., Lapins, A., Shatz, R., & Sawyer, R. P. (2021) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2021.100041 · Cited by 42 · see citing works
Tau; One Protein, So Many Diseases
Tabeshmehr, P., & Eftekharpour, E. (2023) · Biology · doi:10.3390/biology12020244 · Cited by 33 · see citing works
Blood biomarkers in frontotemporal dementia: Review and meta-analysis
Ntymenou, S., Tsantzali, I., Kalamatianos, T., Voumvourakis, K. I., Kapaki, E., Tsivgoulis, G., Stranjalis, G., & Paraskevas, G. P. (2021) · Brain Sciences · doi:10.3390/brainsci11020244 · Cited by 31 · see citing works
- Authors
- Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., Triana-Baltzer, G., Theunis, C., Slemmon, R., Mercken, M., Kolb, H., Dage, J. L., & Hansson, O.
- Affiliations
- Lund University (SE)
- Eli Lilly (United States) (US)
- Janssen (Belgium) (BE)
- Janssen Research & Development (United States) (US)
- Corresponding author
- Janelidze, Shorena
- Kolb, Hartmuth
- Dage, Jeffrey L.
- Hansson, Oskar
- ORCID
- Venue
- Nature Communications
- Published
- 2020-04-03
- Volume
- 11
- Issue
- 1
- Pages
- 1683-1683
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC7125218
- OpenAlex
- W3014779409
- Cited by
- 450
- References
- 20
- Citations by year
- 2026: 45 · 2025: 86 · 2024: 77 · 2023: 52 · 2022: 71 · 2021: 89 · 2020: 29
- FWCI
- 43.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Eli Lilly and Company
- Australian Government
- Lunds Universitet
- Knut och Alice Wallenbergs Stiftelse
- Vetenskapsrådet
- Skånes universitetssjukhus
- Marcus och Amalia Wallenbergs minnesfond
- Parkinsonfonden
- Avid Radiopharmaceuticals
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, p-tau217, p-tau181, tau phosphorylation, 18F-flortaucipir, tau PET, amyloid-beta, differential diagnosis of dementia, longitudinal biomarker changes
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Carbolines, Contrast Media, Diagnosis, Differential, Feasibility Studies, Female, Humans, Male, Middle Aged, Phosphorylation, Sweden, Biomarkers, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
